2 reports

ISCHEMIC HEART DISEASE LOWER RESPIRATORY INFECTIONS COPD TUBERCULOSIS DIABETES MELLITUS ##. ## ##. ## ##. ## ##. ## ##. ## Source: Technavio, 2015 The drug device combination products market in EMEA was valued at $##. ## billion in 2014 and is expected to reach $##. ## billion by 2019, growing at a CAGR

  • Implantable Delivery
  • Becton Property Group
  • Boston Scientific Corporation
  • Medtronic, Inc.
  • Roche Group

It has been proven to have a great curative effect on internal organs and their malfunctions, such as pulmonary tuberculosis bleeding, gastric hemorrhage, intestinal bleeding, internal cranium bleeding, gynecological blood disease and purpura.

  • Implantable Delivery
  • China
  • Demand
  • GlaxoSmithKline plc
  • Yunnan Baiyao Group Co., Ltd.